{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:40:53Z","timestamp":1757612453516,"version":"3.44.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Paragangliomas (PGLs) are pheochromocytomas outside the adrenal glands, most commonly found in the retroperitoneal space, head and neck, bladder, and mediastinum. However, PGL occurring in the liver are extremely rare. We present a case of a 70-year-old woman who presented to our hospital with right upper abdominal pain, persisting for 2 years. Abdominal contrast-enhanced computed tomography (CT) revealed a 3.8 x 2.7 cm hypervascular nodule in the caudate lobe of the liver, demonstrating arterial phase hyperenhancement and portal\/delayed phase washout. Magnetic resonance imaging (MRI) further demonstrated diffusion restriction and low signal intensity in the hepatobiliary phase (HBP) of the nodule. Based on these imaging features, hepatocellular carcinoma (HCC) was initially diagnosed radiologically. Surgical resection was performed, and immunohistochemical staining revealed positivity for chromogranin A (CgA), synaptophysin (Syn), and S - 100 protein, confirming the diagnosis of primary hepatic PGL (HPGL). This case highlights that hypervascular lesions with washout and HBP hypointensity may mimic HCC. Pathological verification is crucial, especially in patients without typical HCC risk factors. Although exceedingly rare, HPGL should be considered in the differential diagnosis of hypervascular hepatic nodules demonstrating typical arterial phase hyperenhancement and portal\/delayed washout on CT\/MRI, particularly in female patients presenting with nonspecific symptoms and lacking typical HCC risk factors such as hepatitis, alcohol abuse, or elevated tumor markers.<\/jats:p>","DOI":"10.3389\/fonc.2025.1570896","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T12:36:38Z","timestamp":1756989398000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: A rare case of primary hepatic paraganglioma: a mimicker of hepatocellular carcinoma"],"prefix":"10.3389","volume":"15","author":[{"given":"Aitong","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/794187","article-title":"Paragangliomas\/pheochromocytomas: clinically oriented genetic testing","volume":"2014","author":"Martins","year":"2014","journal-title":"Int J Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-22-314","article-title":"Primary hepatic paraganglioma mimicking hepatocellular carcinoma: a case report","volume":"11","author":"Li","year":"2022","journal-title":"Transl Cancer Res TCR"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e05310","DOI":"10.1002\/ccr3.5310","article-title":"Paraganglioma masquerading as a primary liver lesion: A rare entity discovered during surgery","volume":"10","author":"Miller","year":"2022","journal-title":"Clin Case Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.4103\/tcmj.tcmj_230_18","article-title":"A primary paraganglioma of the liver mimicking hepatocellular carcinoma","volume":"31","author":"Lin","year":"2019","journal-title":"Tzu-Chi Med J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e0293","DOI":"10.1097\/MD.0000000000010293","article-title":"Primary functioning hepatic paraganglioma mimicking hepatocellular carcinoma: A case report and literature review","volume":"97","author":"Liao","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.3318","article-title":"Primary Malignant hepatic paraganglioma mimicking liver tumor: A case report","volume":"10","author":"You","year":"2015","journal-title":"Oncol Lett"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/0895-7061(96)00174-4","article-title":"Primary hepatic pheochromocytoma","volume":"9","author":"Reif","year":"1996","journal-title":"Am J Hypertens"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/BF00619965","article-title":"Primary hepatic pheochromocytoma","volume":"6","author":"Rimmelin","year":"1996","journal-title":"Eur Radiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6060(05)80260-0","article-title":"Primary hepatic pheochromocytoma: A second case","volume":"117","author":"Jaeck","year":"1995","journal-title":"Surgery"},{"key":"B12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40200-016-0226-x","article-title":"Does this patient have Pheochromocytoma? a systematic review of clinical signs and symptoms","volume":"15","author":"Soltani","year":"2016","journal-title":"J Diabetes Metab Disord"},{"key":"B13","doi-asserted-by":"publisher","first-page":"20420188231207544","DOI":"10.1177\/20420188231207544","article-title":"Pheochromocytoma: a changing perspective and current concepts","volume":"14","author":"Kiriakopoulos","year":"2023","journal-title":"Ther Adv Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0882","article-title":"Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma","volume":"170","author":"van Berkel","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11906-018-0804-z","article-title":"Pheochromocytomas and hypertension","volume":"20","author":"Pappachan","year":"2018","journal-title":"Curr Hypertens Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0006","article-title":"Unenhanced CT imaging is highly sensitive to exclude pheochromocytoma: a multicenter study","volume":"178","author":"Buitenwerf","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1102\/1470-5206.2012.0016","article-title":"Pheochromocytoma and paraganglioma: imaging characteristics","volume":"12","author":"Baez","year":"2012","journal-title":"Cancer Imaging"},{"key":"B18","doi-asserted-by":"publisher","first-page":"492","DOI":"10.2214\/AJR.05.0370","article-title":"Extraadrenal paragangliomas of the body: imaging features","volume":"187","author":"Lee","year":"2006","journal-title":"Am J Roentgenol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/1754-9485.13809","article-title":"Paraganglioma and phaeochromocytoma in adult Fontan patients","volume":"69","author":"Tan","year":"2024","journal-title":"J Med Imag Rad Onc"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-15-0261","article-title":"15 YEARS OF PARAGANGLIOMA: Pathology of pheochromocytoma and paraganglioma","volume":"22","author":"Tischler","year":"2015","journal-title":"Endocrine-Rel Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0494","article-title":"Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma","volume":"21","author":"Kimura","year":"2014","journal-title":"Endocrine-Rel Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.00829","article-title":"Malignant pheochromocytoma: current status and initiatives for future progress","volume":"11","author":"Eisenhofer","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.07.025","article-title":"aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis","volume":"73","author":"Fan","year":"2020","journal-title":"J Hepatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ijnss.2023.09.009","article-title":"Symptoms and symptom clusters in patients with hepatocellular carcinoma and commonly used instruments: An integrated review","volume":"11","author":"Pathomjaruwat","year":"2024","journal-title":"Int J Nurs Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.20517\/2394-5079.2021.131","article-title":"Hepatocellular carcinoma surveillance: current practice and future directions","volume":"8","author":"Ahn","year":"2022","journal-title":"Hepatoma Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-023-00890-0","article-title":"An insight into the role of alpha-fetoprotein (AFP) in the development and progression of hepatocellular carcinoma","volume":"66","author":"Samban","year":"2024","journal-title":"Mol Biotechnol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2018181494","article-title":"Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients","volume":"289","author":"Chernyak","year":"2018","journal-title":"Radiology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-022-05382-1","article-title":"A comprehensive review of hepatic hemangioma management","volume":"26","author":"Aziz","year":"2022","journal-title":"J Gastrointest Surg"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002857","article-title":"ACG clinical guideline: focal liver lesions","volume":"119","author":"Frenette","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1148\/rg.220056","article-title":"Liver metastases: correlation between imaging features and pathomolecular environments","volume":"42","author":"Ozaki","year":"2022","journal-title":"Radiographics"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.058701","article-title":"Usefulness of123 I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial","volume":"50","author":"Wiseman","year":"2009","journal-title":"J Nucl Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1570896\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T12:36:41Z","timestamp":1756989401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1570896\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":31,"alternative-id":["10.3389\/fonc.2025.1570896"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1570896","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"article-number":"1570896"}}